Analysis of invasive pneumonia-causing strains of Streptococcus pneumoniae: serotypes and antimicrobial susceptibility

Show simple item record

dc.contributor Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP
dc.contributor.author YOSHIOKA, Cristina R. M. FMUSP-HC
MARTINEZ, Marina B.
BRANDILEONE, Maria C. C.
RAGAZZI, Selma B. FMUSP-HC
GUERRA, Maria L. L. S.
SANTOS, Silvia R.
SHIEH, Huei H. FMUSP-HC
GILIO, Alfredo E. FMUSP-HC
dc.date.issued 2011
dc.identifier.citation JORNAL DE PEDIATRIA, v.87, n.1, p.70-75, 2011
dc.identifier.issn 0021-7557
dc.identifier.uri http://observatorio.fm.usp.br/handle/OPI/23298
dc.description.abstract Objectives: To identify the most common pneumococcal serotypes in children hospitalized with invasive pneumonia, correlate isolated serotypes with those included in conjugate vaccines, and ascertain the sensitivity of the isolated pneumococcal strains to penicillin and other antibiotics. Methods: From January 2003 to October 2008, a retrospective study of hospitalized children with a diagnosis of Streptococcus pneumoniae pneumonia was conducted at the university hospital of Universidade de Sao Paulo. Criteria for inclusion were: age greater than 29 days and less than 15 years, radiological and clinical diagnosis of pneumonia, and isolation of Streptococcus pneumoniae in blood cultures and/or pleural effusion. Results: The study included 107 children. The most common serotypes were 14 (36.5%), 1 (16%), 5 (14.6%), 6B (6.3%) and 3 (4.2%). The proportion of identified serotypes contained in the heptavalent, 10-valent and 13-valent conjugate vaccines was 53.1, 86.5, and 96.9%, respectively. Pneumococcal strains were sensitive to penicillin (minimum inhibitory concentration, MIC <= 2 mu g/mL) in 100 cases (93.5%) and displayed intermediate resistance (MIC = 4 mu g/mL) in 7 cases (6.5%). No strains were penicillin-resistant (MIC >= 8 mu g/mL) according to the Clinical and Laboratory Standards Institute 2008 standards. Tested isolates were highly sensitive to vancomycin, rifampicin, ceftriaxone, clindamycin, erythromycin, and chloramphenicol. Conclusions: Our results confirm a significant potential impact of conjugate vaccines, mainly 10-valent and 13-valent, on invasive pneumonia. Furthermore, susceptibility testing results show that penicillin is still the treatment of choice for invasive pneumonia in our setting.
dc.language.iso por
dc.publisher SOC BRASIL PEDIATRIA
dc.relation.ispartof Jornal de Pediatria
dc.rights openAccess
dc.subject Streptococcus pneumoniae; pneumonia; serotype; antimicrobial resistance; pneumococcal conjugate vaccine
dc.subject.other community-acquired pneumonia; pneumococcal pneumonia; penicillin susceptibility; united-states; children; resistance; disease; breakpoints; infections; prevalence
dc.title Analysis of invasive pneumonia-causing strains of Streptococcus pneumoniae: serotypes and antimicrobial susceptibility
dc.type article
dc.rights.holder Copyright SOC BRASIL PEDIATRIA
dc.identifier.doi 10.2223/JPED.2063
dc.identifier.pmid 21327303
dc.type.category original article
dc.type.version publishedVersion
hcfmusp.author YOSHIOKA, Cristina R. M.:FM:
hcfmusp.author RAGAZZI, Selma B.:HU:SCPAINT-62
hcfmusp.author SHIEH, Huei H.:HU:PAINT-62
hcfmusp.author GILIO, Alfredo E.:FM:MPE
hcfmusp.author.external · MARTINEZ, Marina B.:Univ Sao Paulo, Univ Hosp, Lab Anal Clin, Sao Paulo, Brazil; Univ Sao Paulo, Fac Ciencias Farmaceut, Sao Paulo, Brazil
· BRANDILEONE, Maria C. C.:Univ Fed Sao Paulo, EPM, Sao Paulo, Brazil; IAL, Projeto SIREVA Secao Bacteriol 2, Sao Paulo, Brazil
hcfmusp.origem.id WOS:000288225400012
hcfmusp.origem.id 2-s2.0-79951778693
hcfmusp.publisher.city RIO DE JANEIRO, RJ
hcfmusp.publisher.country BRAZIL
hcfmusp.relation.reference · FRIEDLAND IR, 1992, AM J DIS CHILD, V146, P920
· Brueggemann AB, 2004, J INFECT DIS, V190, P1203, DOI 10.1086/423820
· [Anonymous], 1997, PEDIATRICS, V99, P289
· Whitney CG, 2000, NEW ENGL J MED, V343, P1917, DOI 10.1056/NEJM200012283432603
· Di Fabio JL, 2001, PEDIATR INFECT DIS J, V20, P959, DOI 10.1097/00006454-200110000-00009
· Reingold A., 2008, Morbidity and Mortality Weekly Report, V57, P1353
· Heffelfinger JD, 2000, ARCH INTERN MED, V160, P1399, DOI 10.1001/archinte.160.10.1399
· PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802
· Hausdorff WP, 2000, CLIN INFECT DIS, V30, P100, DOI 10.1086/313608
· Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8
· Rudan I, 2008, B WORLD HEALTH ORGAN, V86, P408, DOI 10.2471/BLT.07.048769
· Rudan I, 2004, B WORLD HEALTH ORGAN, V82, P895
· Yu VL, 2003, CLIN INFECT DIS, V37, P230, DOI 10.1086/377534
· Brandileone MCC, 2006, J MED MICROBIOL, V55, P567, DOI 10.1099/jmm.0.46387-0
· Song JH, 2004, CLIN INFECT DIS, V38, P1570, DOI 10.1086/420821
· Berezin EN, 1996, PEDIATR INFECT DIS J, V15, P1051, DOI 10.1097/00006454-199611000-00027
· Bryan CS, 1997, CHEST, V112, P1657, DOI 10.1378/chest.112.6.1657
· Castaneda E, 2009, PEDIATR INFECT DIS J, V28, P265, DOI 10.1097/INF.0B013E3181A74B22
· Clinical and Laboratory Standards Institute, 2008, CLSI PUBL, V28
· Giachetto G, 2004, PEDIATR INFECT DIS J, V23, P625, DOI 10.1097/01.inf.0000128783.11218.c9
· Hathaway LJ, 2007, MICROBIOL-SGM, V153, P2465, DOI 10.1099/mic.0.2006/005066-0
· Nascimento-Carvalho Cristiana N, 2003, J Pediatr (Rio J), V79, P209, DOI 10.1590/S0021-75572003000300005
· *ORG PAN SALUD, 2009, INF REG SIR 2008 DAT
· PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104
· Shouval DS, 2009, PEDIATR INFECT DIS J, V28, P277, DOI 10.1097/INF.0b013e31818e0e2e
· Wolkers PCB, 2009, J PEDIAT-BRAZIL, V85, P421, DOI [10.2223/JPED.1931, 10.1590/S0021-75572009000500009]
dc.description.index MEDLINE
hcfmusp.citation.scopus 12
hcfmusp.citation.wos 11
hcfmusp.affiliation.country Brasil


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace



Browse

My Account

Statistics